• ERAD-Hijacking Chimeras Enable Selective TM Protein Degradat

  2026-07-26

  Song et al. introduce ERAD-engaging chimeras (ERADECs), a small-molecule platform that selectively degrades transmembrane proteins by hijacking the ER-associated degradation pathway. This approach overcomes longstanding barriers in targeted protein degradation, opening new avenues for both basic research and therapeutic strategies targeting membrane proteins.

• Flumequine in Precision Cancer Assays: Beyond Topoisomerase

  2026-07-25

  Explore the advanced utility of Flumequine as a DNA topoisomerase II inhibitor in modern cancer research. This article provides an in-depth analysis of assay design, practical workflow decisions, and nuanced interpretation of drug response metrics.

• Mono-ADP-Ribosylation as a Degradation Signal: Insights into

  2026-07-24

  This study reveals that endogenous mono-ADP-ribosylation marks proteins such as PARP7 and the aryl hydrocarbon receptor (AHR) for degradation, establishing a new paradigm for post-translational regulation. By blocking the ubiquitin pathway, the authors provide evidence for direct crosstalk between ADP-ribosylation and ubiquitin-mediated proteolysis in cell signaling and protein turnover.

• FAISL lncRNA Blocks FAK Degradation to Drive TNBC Metastasis

  2026-07-24

  The reference study uncovers lncRNA FAISL as a stabilizer of FAK protein, promoting progression and metastasis of triple negative breast cancer (TNBC) by blocking Calpain 2-mediated FAK degradation. This mechanistic insight highlights a novel regulatory axis and suggests new therapeutic targets for aggressive breast cancer subtypes.

• Olive Biophenols Mitigate Alzheimer’s Pathology in Cell and

  2026-07-23

  The referenced study demonstrates that natural olive biophenols, particularly oleuropein, verbascoside, and rutin, reduce amyloid-beta (Aβ) aggregation and toxicity in both SH-SY5Y neuroblastoma cells and transgenic Alzheimer’s disease (AD) model mice. These findings highlight the disease-modifying potential of plant-derived biophenols for targeting key mechanisms underlying AD pathology, with implications for translational research and therapeutic development.

• Polymyxin B (sulfate): Data-Driven Solutions for Lab Assays

  2026-07-23

  This article provides scenario-driven guidance on using Polymyxin B (sulfate) (SKU C3090) for reliable Gram-negative bacterial infection research, cell viability workflows, and immunomodulatory assays. Emphasizing evidence-based optimization, it addresses common laboratory challenges in protocol design, data interpretation, and vendor selection.

• Proteomic Effects of HSP90 Inhibition in Lung Adenocarcinoma

  2026-07-22

  This study systematically maps how HSP90 inhibition alters the proteomic landscape of lung adenocarcinoma cells, revealing key changes in signaling pathways and candidate biomarkers such as eIF3i and citrate synthase. The findings refine our understanding of chaperone-targeted therapies and inform strategies for overcoming resistance and optimizing future cancer research assays.

• Optimized hGBA1 mRNA Restores Lysosomal GCase in Gaucher Mod

  2026-07-22

  The referenced study presents a rational design and optimization of human GBA1 mRNA, achieving robust, durable expression of functional glucocerebrosidase (GCase) in cellular and animal models of Gaucher disease. This approach demonstrates significant advances over conventional therapies, offering new possibilities for mRNA-based interventions and lysosomal enzyme activity research.

• Actinomycin D: Precision Tool for Transcriptional Inhibition

  2026-07-21

  Explore how Actinomycin D (ActD) enables precise transcriptional inhibition and apoptosis induction in advanced cell and molecular biology research. This article uniquely bridges ActD’s mechanistic depth with its critical role in stem cell differentiation and assay design.

• Hepatic Cellular Uptake of PEGylated Iron Oxide Nanoparticle

  2026-07-21

  This study systematically dissects how PEG chain length and nanoparticle size dictate the hepatic distribution and cellular uptake of iron oxide nanoparticles. Unexpectedly, hepatocytes and hepatic stellate cells, not Kupffer cells, emerge as principal mediators of hepatic nanoparticle accumulation, offering actionable guidance for nanomedicine design.

• Metoprolol Tartrate: β1-Selective Blockade and Engraftment F

  2026-07-20

  Explore how Metoprolol Tartrate, a selective β1-adrenergic blocking agent, underpins advanced cardiovascular and hematopoietic research. This article offers a novel perspective on assay design and stem cell engraftment, revealing insights not covered in existing guides.

• Metal-Free Carbon Nanozymes Enable Sensitive ALP Detection

  2026-07-20

  This study pioneers a metal-free carbon dot nanozyme assay for highly sensitive and selective alkaline phosphatase (ALP) detection. Its colorimetric approach circumvents metal-associated cytotoxicity and interference, advancing reliable enzymatic assays in complex biological samples. These findings have direct implications for metabolic profiling and diagnostic research.

• MPC, Lactate, and Histone Lactylation Shape Tumor Immunity

  2026-07-19

  This study uncovers how downregulation of the mitochondrial pyruvate carrier (MPC) in colorectal cancer elevates lactate production, which in turn drives histone lactylation in dendritic cells. These metabolic-epigenetic changes impair CD8+ T cell responses and diminish immunotherapy efficacy, highlighting MPC as a promising target for tumor microenvironment modulation.

• Strategic Mechanistic Screening: Reimagining FDA Library Uti

  2026-07-18

  This thought-leadership article explores how the DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) empowers translational researchers to bridge mechanistic insights and actionable therapies. Drawing from recent breakthroughs in engineered extracellular vesicle delivery and leveraging robust, clinically validated chemical diversity, the article delivers practical guidance for protocol optimization, cross-domain innovation, and future-ready drug repositioning strategies.

• Cimetidine’s Translational Edge: Mechanisms, Models, and Str

  2026-07-17

  This article unveils how Cimetidine’s distinct partial agonist activity at the H2 receptor empowers translational researchers to probe cancer and blood-brain barrier mechanisms more deeply than with conventional antagonists. Integrating mechanistic insight, strategic guidance, and the latest in vitro model advances, it positions Cimetidine (APExBIO, SKU B1557) as a pivotal tool for high-impact discovery and predictive validation in preclinical workflows.

450 records 10/30 page Previous Next First page 上5页 678910 下5页 Last page